C
rohn's disease (CD) is a chronic, frequently progressive inflammatory disorder characterized by an exaggerated mucosal immune response of the gastrointestinal system in a genetically susceptible individual. 1 CD and ulcerative colitis are the 2 major clinical phenotypes and affect approximately 1 in 200 people in the Western world, with an increasing prevalence in developing countries. [2] [3] [4] More than 50% of children are expected to develop complicated disease behavior (stricturing and/or penetrating behavior) by 5 years after diagnosis. Disease progression is worse in children compared with adults. 5 The impact of medical management on disease progression and on surgical rates remains controversial. We previously reported, using data from this same patient registry, that the 5-year risk of bowel surgery in pediatric CD was 13.8%. 27 Retrospective pediatric studies have reported the 5-year risk of surgery to be between 14.2% and 34%. [28] [29] [30] Our primary goal was to determine the 10-year surgical risk in children with CD. Our secondary goal was to determine if the early use of biologics (anti-tumor necrosis factor [TNF]a) influenced the risk of disease progression.
Materials and Methods

Study Population
The Pediatric Inflammatory Bowel Disease Collaborative Research Group registry was established by 26 North American pediatric inflammatory bowel disease (IBD) centers in 2002 to study the contemporary natural history of IBD. Newly diagnosed children 16 years of age and younger were enrolled. Patients were managed according to the practice of their individual physician. Uniform data were collected at diagnosis, 30 days after diagnosis, and then quarterly and during hospitalizations. Between January 2002 and December 2014, the registry enrolled 2116 pediatric IBD patients. The 1442 CD patients (68% of the total) constitute the study population of this report.
Outcomes
The outcomes of interest were time from diagnosis to (a) first intestinal surgery and (b) time to progression to stricturing and/or penetrating disease.
Description of Variables
Day 0 was defined as the date of initial diagnosis. The study end date for patients who had a CD-related surgery was the date of the first bowel surgery. The patients who did not have surgery had a study end date defined by the last quarter of follow-up evaluation, which also was used to censor values in time-to-event analyses. Bowel surgery was defined as intestinal resection with primary anastomosis or diverting ostomy (including subtotal and total colectomy) or strictureplasty. Other surgical procedures such as abdominal or perianal abscess drainage, or fistulotomy, were excluded. Family history of IBD was defined as having an affected mother, father, or sibling. Disease location was recorded within 30 days of diagnosis. The presence of endoscopic, histologic, or radiologic disease was recorded for the esophagus, gastroduodenum, jejunum, ileum, right colon, transverse colon, left colon, and for disease of the sigmoid colon and/or rectum. Disease location was classified as esophagus to jejunum, ileum to right colon, and transverse colon to rectum. Disease behavior was recorded at baseline, 30 days after diagnosis, and then quarterly. Disease behavior was defined as nonstricturing, nonpenetrating (inflammatory) disease (B1), stricturing (B2), and penetrating disease (B3). If a patient had a missing disease behavior for a particular quarter, the previous quarter's disease behavior was carried forward. Disease progression was defined as change from inflammatory only to either stricturing or penetrating or both. Regarding treatments, use of biologics was considered "early" if patients were started during the first quarter after diagnosis and completed their induction phase. 20 Immunomodulator use was defined if the use of 6-mercaptopurine, azathioprine, or methotrexate was documented for more than 1 quarter.
Statistical Methods
The Kaplan-Meier method was used to estimate survival functions with 95% CIs for first bowel surgery, first nonbowel surgery, and all first CD-related surgery. The Wilcoxon weighting of the chi-square statistic was used when comparing subsets of patients (weighting by changing sample size over time). The family wise a value was maintained at .05 across multiple comparisons using a Tukey adjustment of the raw P values. Proportional hazards (Cox) regression with time-varying covariates was used to model time-to-event outcomes with timevarying covariates. Disease severity was dummy coded as stricturing or penetrating disease relative to inflammatory disease. Age was treated as continuous. All statistical analyses were performed using SAS version 9.4 (The SAS Institute, Inc, Cary, NC).
The protocol for the Pediatric Inflammatory Bowel Disease Collaborative Research Group registry was approved by the institutional review boards of all participating institutions, and informed consent/ assent was obtained at the time of enrollment in the registry.
Results
Demographics
Demographics and disease characteristics for the 1442 CD patients enrolled in our study are shown in Table 1 .
Risk of Crohn's Disease-Related Bowel Surgery
The Kaplan-Meier estimated risk of CD-related bowel surgery was 4% at 1 year, 13% at 5 years, and 26% at 10 years ( Figure 1A ). A total of 241 subjects underwent any type of surgery, 171 of these had bowel-related surgery (Table 2) . Figure 1B shows the monthly occurrence of the 171 bowel surgeries since the diagnosis. Two patients (1%) underwent bowel resection at diagnosis and were not included in our analyses, 66% of first bowel surgeries occurred within 36 months from diagnosis and the remaining 33% occurred over the last 84 months of the study.
Specific Risks for Surgery
Patients with stricturing and/or penetrating disease behavior at diagnosis were at a significantly higher risk of surgery over time (P ¼ .001) ( Figure 1C ). Table 3 shows the risk of surgery for subsets of patients based on age, sex, and disease behavior. Overall, our analyses show that over time neither age of the patient (P ¼ .05), disease location at diagnosis (P ¼ .8), year of diagnosis (P ¼ .6), nor presence of perianal disease (P ¼ .4) predict differences in the risk of surgery. There was also no difference in the 5-year risk of surgery between patients who entered the study between 2002 and 2007 and those enrolled between 2008 and 2014 (Figure 2A) , despite an increased use of biologics ( Figure 2B ) and the earlier initiation of biologics ( Figure 2C) .
No significant effects on disease progression were identified for nonbiologic treatments.
Impact of Treatment on Disease Progression
Among patients who received a biologic agent at any time during the study (including the first 3 months), the risk of disease progression to stricturing or penetrating disease was statistically significantly reduced by biologic use as analyzed by proportional hazards (Cox) regression with biologic use as a time-varying covariate (hazard ratio, 0.85; 95% CI, 0.76-0.95; P ¼ .005). No significant effect on surgery was found.
We examined the impact of biologics on disease progression in children with inflammatory (B1) disease. Of the 1291 patients with B1 disease at diagnosis, 145 patients had been started by their pediatric gastroenterologists on biologics within the first 3 months after diagnosis. Analyses ( Figure 3A ) of those who were treated early showed that disease progression from B1 to B2 or B3 after 5 years was decreased when compared with those not receiving early biologics (P < .005). No statistically significant effect was found on progression to surgery. We could not show a significant impact on any outcome in those groups in which the biologics were started after the first 3 months.
Interestingly, Figure 3B shows that patients with B1 disease, exposed to biologics in the first quarter of their disease, seemed more likely to have early surgery than those with B1 disease who were not started on biologics.
Discussion
The long-term effect of current IBD therapies, especially biologics, in children is not clear. 25, 26 Recently Kugathasan et al 20 showed that children enrolled in the Risk Stratification and Identification of Immunogenic and Microbial Markers of Rapid Disease Progression in Children with Crohn's (RISK) 20 cohort, who received early (within the first 3 months from diagnosis) anti-TNFa therapy, showed a reduction in penetrating disease but not stricturing disease within their first 4 years after diagnosis. Our study was not able to show an effect on disease progression within a timeframe similar to that of the RISK study. We were, however, able to show an overall effect on disease progression after 5 years. The difference reflects the differences in study populations. The RISK study 20 included only children who were still classified as having inflammatory (B1) disease at 90 days after diagnosis, excluding children with disease progression within 3 months of diagnosis. We included those children. By including many children in whom early disease progression already had taken place, we lessened our ability to show an early effect on their group as a whole. More than 15% of our cohort already had their first bowel-related surgery in the first 90 days after diagnosis ( Figure 1B ). The 5-year risk of surgery in our prospective cohort was 13%, and the 10-year risk was 26% ( Figure 1A ). This is identical to a recent single-center retrospective study in children published by an Israeli group. 28 However, the risk is lower than all other published pediatric and adult studies. 29, 30 The difference may be related to this being a true inception cohort of patients, or to the era of diagnosis. The surgical rates are less when compared with most of the population-based cohorts in adults, suggesting that the risk of surgery may be different in pediatric Crohn's disease compared with adult-onset Crohn's disease. However, the 5-year risk of surgery did not change significantly when comparing cohorts diagnosed between 2002 and 2007 (13.8%) 27 and 2008 and 2014 (13%) (Figure 2A ). This is true despite the documented earlier and increasingly frequent use of biologics over the course of the study ( Figure 2B and C) .
Disease behavior (inflammatory vs stricturing vs penetrating) at diagnosis was the best predictor of surgery ( Figure 1C) . None of the other disease characteristics at diagnosis such as disease location, sex, age at onset, year of diagnosis, or center from which patient was recruited predicted surgery.
Although several studies have shown that disease location does not predict the risk of surgery, 31-33 a recent study by Cleynen et al, 14 one of the larger genotype-phenotype correlation studies of IBD, showed that the risk of surgery was low in colonic disease compared with those with ileocolonic/ileal disease.
Our results reflect the natural progression of CD over 10 years. Our analysis shows that the use of biologics is associated with slowing disease progression from inflammatory to stricturing/penetrating (hazard ratio, 0.85; 95% CI, 0.76-0.95; P ¼ .005). Our work extends the findings recently reported by Kugathasan et al, 20 that early anti-TNFa therapy was associated with a reduction in penetrating disease generally occurring within a 2-year period. They suggest that a specific ileal extracellular matrix protein gene signature present at diagnosis predicted stricturing disease in pediatric Crohn's disease. We suggest that their exclusion of patients with disease progression occurring in the first 90 days skews their study population toward a less severe group than we are reporting and toward a group more able to show response to early treatment. Most importantly, both reports support the positive impact of early therapy with biologics to prevent the significant complications associated with disease progression.
It should be noted that we found that in the group receiving early biologics (n ¼ 145), the risk of surgery appears to be increased paradoxically in the first 5 years after diagnosis ( Figure 2B ). This suggests that our practicing pediatric gastroenterologists may have selected the sicker patients to start biologics. If this is the case then this introduces a bias that strengthens our findings because it would be the sicker patients who are, in our study, experiencing the better long-term outcome (ie, less disease progression).
The strengths of our study include its long-term follow-up period, its large sample size, and being a true inception cohort (ie, inclusion of children within the first 30 days from diagnoses). These enable us to better assess temporal trends associated with the incidence of surgery. There were limitations, however, of the study. This study was started more than 15 years ago and conceived before our current ability to collect and process biological samples and to monitor anti-TNFa blood levels. As a registry-based study, disease location data were not universally available on follow-up evaluation, endoscopic and pathologic data were not collected uniformly, and variation in practice at different centers may have influenced the results. Even though details of the treatment were documented, we do not have information about whether therapeutic drug monitoring of biologics or immunomodulators were used to optimize these treatments during the study. Another important limitation was the decrease in the number of patients over time, similar to other prospective cohort studies. Some of these limitations also limit the analytic approaches available to us.
Overall, this study provides important information about temporal trends of surgical risk in pediatric Crohn's disease. The initial 5-year risk of surgery has not changed over the 12 years of our study despite the use of newer therapies. We believe that this may reflect significant subclinical and clinical disease progression before diagnosis and before current medications capable of altering disease course are used. However owing to limitation of the registry model, we could not prove that surgery would decrease with earlier or more aggressive biologic use.
Taken together, our work and the work of Kugathasan et al 20 present a picture consistent with the view that a critical factor in preventing bowel complications of IBD is starting effective treatment early, before the accumulation of significant bowel damage. Figure 3. (A) Disease progression from inflammatory to stricturing and/or penetrating compared between the early initiation of biologics group (use of biologics in the first 3 months) and the no early exposure to biologics groups (did not receive biologics in the first 3 months). The x-axis show the follow-up period in years since the diagnosis, and the y-axis shows the proportion of patients without disease progression (ie, change of behavior from inflammatory to stricturing and/or penetrating.) (B) Cumulative risk of surgery among early initiation of biologics (within the first 3 months) compared with those who did not receive biologics in the first 3 months. The x-axis shows the years since the diagnosis, and the y-axis shows surgery-free survival. Note that those patients who received biologics within the first 3 months after diagnosis showed shorter surgery-free survival.
